All In Biotech

Drug Trial Radar · NCT04121286

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Jul 14, 2020

Primary completion

Jun 17, 2022

Study completion Jun 17, 2022

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

Conditions

  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Ductal Carcinoma
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Breast Cancer
  • Other Solid Tumors

Interventions

  • JAB-3312Drug

    JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicitiesTime frame: Approximately 2 years
  2. Find Recommended Phase 2 Dose (RP2D) of JAB-3312Time frame: Approximately 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical Collage Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Henan Provovential Cancer Hospital

    Henan, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.